Stockscreener 앱 받기
0.3987
0.10%
0.0004
시간 외 거래:
.41
0.0113
+2.83%
전일 마감가:
$0.3983
열려 있는:
$0.3956
하루 거래량:
1.38M
Relative Volume:
0.57
시가총액:
$47.09M
수익:
-
순이익/손실:
$-119.76M
주가수익비율:
-0.2953
EPS:
-1.35
순현금흐름:
$-55.17M
1주 성능:
+19.73%
1개월 성능:
-27.42%
6개월 성능:
-95.27%
1년 성능:
-90.57%
1일 변동 폭
$0.3867
$0.4103
1주일 범위
$0.3051
$0.4284
52주 변동 폭
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
명칭
Applied Therapeutics Inc
전화
212-220-9226
주소
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
APLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.3987 | 47.09M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-23 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-02 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-31 | 개시 | William Blair | Outperform |
| 2024-03-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-22 | 개시 | Leerink Partners | Outperform |
| 2022-01-04 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-08-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-04-22 | 개시 | Goldman | Buy |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-06-10 | 개시 | Citigroup | Buy |
| 2019-06-10 | 개시 | Cowen | Outperform |
| 2019-06-10 | 개시 | Robert W. Baird | Outperform |
모두보기
Applied Therapeutics Inc 주식(APLT)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Applied Therapeutics Inc (NASDAQ:APLT)’s 12-Month Price Target Is Now Set At 5. - Marketing Sentinel
APLT stock touches 52-week low at $0.3 amid sharp annual decline By Investing.com - Investing.com South Africa
APLT stock touches 52-week low at $0.3 amid sharp annual decline - Investing.com
Applied Therapeutics Reports 2024 Financial Results and Leadership Changes - TipRanks
Applied Therapeutics, Inc. SEC 10-K Report - TradingView
Applied Therapeutics (APLT) Reports Lower Revenue But Reinforces Strategic Focus | APLT Stock News - GuruFocus
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Fi - GuruFocus
Applied Therapeutics earnings beat by $0.71, revenue fell short of estimates - Investing.com Canada
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results - The Manila Times
Applied Therapeutics Strengthens Balance Sheet: $79.4M Cash Position Powers Drug Development Push - Stock Titan
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results | APLT Stock News - GuruFocus
Norges Bank Acquires New Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics LawsuitAPLT - ACCESS Newswire
APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Applied Therapeutics, Inc.(APLT) should contact The Gross Law Firm about pending Class ActionAPLT - MarketScreener
APLT stock touches 52-week low at $0.42 amid sharp annual decline - Investing.com Australia
Investors Who Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky About Pending Class ActionAPLT - ACCESS Newswire
APLT stock touches 52-week low at $0.42 amid sharp annual decline By Investing.com - Investing.com South Africa
Applied Therapeutics, Inc. (APLT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Class Action Filed Against Applied Therapeutics, Inc. (APLT) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
APLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Charles Schwab Investment Management Inc. Has $600,000 Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics Delays Yearly Report Filing - TipRanks
Applied Therapeutics files Form 12b-25 with SEC - TipRanks
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission - GlobeNewswire
Applied Therapeutics Requests SEC Extension: What This Means for 2024 Financial Results - Stock Titan
146,900 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Swiss National Bank - Defense World
Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Lost Money on Applied Therapeutics, Inc.(APLT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Applied Therapeutics appoints new Chief Regulatory Officer By Investing.com - Investing.com South Africa
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer - citybiz
APLT DEADLINE ALERT: Applied Therapeutics Investors have until February 18 before Expiration of the Class Action DeadlineContact BFA Law if You Lost Money - Louisiana First News
Applied Therapeutics Names Todd Baumgartner As Chief Regulatory Officer - Nasdaq
Applied Therapeutics appoints new Chief Regulatory Officer - Investing.com
Applied Therapeutics Strengthens Drug Approval Push With 12-Time FDA Success Veteran - Stock Titan
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) Price Target at $6.10 - MarketBeat
Applied Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire
Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Applied Therapeutics Inc (APLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Applied Therapeutics Inc 주식 (APLT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
| Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
| Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
| Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
| Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
| Funtleyder Leslie D. | Chief Financial Officer |
Aug 22 '24 |
Sale |
5.83 |
13,530 |
78,880 |
277,911 |
| Perfetti Riccardo | Chief Medical Officer |
Aug 22 '24 |
Sale |
5.83 |
22,681 |
132,230 |
986,853 |
| Shendelman Shoshana | President and CEO |
Aug 13 '24 |
Sale |
6.18 |
357,423 |
2,208,874 |
4,810,430 |
| Shendelman Shoshana | President and CEO |
Aug 12 '24 |
Sale |
5.98 |
300,000 |
1,794,000 |
5,167,853 |
| Shendelman Shoshana | President and CEO |
Aug 14 '24 |
Sale |
5.93 |
119,591 |
709,175 |
4,690,839 |
0.24%
36.06%
자본화:
|
볼륨(24시간):